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 3 
ABSTRACT (max 250 words) 51 
Background:  Infectious disease pandemics (IDP) pose a considerable global threat and can 52 
disproportionately affect vulnerable populations including children. Pediatric clinical research 53 
in pandemics is essential to improve children’s healthcare and minimize risks of harm by 54 
interventions that lack an adequate evidence base for this population. The unique features of 55 
IDPs require consideration of special processes to facilitate clinical research. We aimed to 56 
obtain consensus on pediatric clinician-researchers’ perceptions of the priorities to feasibly 57 
conduct clinical pediatric pandemic research in Europe. 58 
Methods: Mixed method study in 2 stages, recruiting pediatric clinician-researchers with 59 
experience of conducting pediatric infectious disease (ID) research in clinical settings in 60 
Europe. Stage one was an expert stakeholder workshop and interviews. Discussions focused 61 
on participant’s experience of conducting pediatric ID research and processes to facilitate 62 
pandemic research. Information informed stage two; an on-line consensus survey to identify 63 
pediatric clinician-researchers priorities to enable IDP research.  64 
Results: Twenty-three pediatric clinician-researchers attended the workshop and thirty-nine 65 
completed the survey. Priorities were primarily focused on structural and operational 66 
requirements of research design and regulation: 1) Clarity within the European Clinical Trials 67 
Directive for pediatric pandemic research; 2) Simplified regulatory processes for research 68 
involving clinical samples and data; and 3) Improved relationships between regulatory bodies 69 
and researchers.  70 
Conclusions: Results suggest that changes need to be made to the current regulatory 71 
environment to facilitate and improve pediatric research in the pandemic context. These 72 
findings can provide expert evidence to research policy decision makers and regulators and to 73 
develop a strategy to lobby for change.  74 
 75 
 4 
INTRODUCTION 1 
Infectious diseases with pandemic potential pose a considerable global threat.(1) Clinical 2 
research is essential to ensure evidence-based public health responses and patient 3 
management in future infectious disease pandemics (IDPs). The unique nature of IDPs 4 
presents challenges to the conduct of research, as implementation must be rapid and 5 
potentially include multiple countries. Strategies to facilitate IDP research include fast track 6 
regulatory approval, pre-approved protocols, alternative consent models, novel trial designs 7 
and stakeholder engagement.(2-4)  8 
In considering IDP research, the populations that may be affected should be considered. For 9 
example, pandemic influenza can disproportionately affect different populations in 10 
comparison to seasonal influenza. During the 2009 (H1N1) pandemic, children, adolescents 11 
and younger adults had the highest burden of disease, and there were severe and fatal cases in 12 
children with no pre-existing risk factors.(5-10)  13 
While children and young people (YP) are an obvious and relevant group to include in 14 
clinical research they are frequently not recruited into trials.(11, 12) There may be a number 15 
of reasons for this including the perceptions that including them is difficult, that approvals 16 
may be subject to greater delay and some clinicians are reluctant to approach parents of sick 17 
children about research participation. However, families are generally willing to be 18 
approached about research even in stressful situations.(13-15) Excluding children and YP 19 
from research has resulted in a lack of evidence for many medical interventions for this group 20 
and the practice to use off-label and unlicensed medicines guided only by clinicians’ 21 
experience and extrapolation of adult data.(16, 17)  22 
There were few clinical research studies in the last influenza pandemics thus limiting the 23 
evidence base for improved care in the future.(18) For example, following recommendations 24 
by organizations including the World Health Organization, Oseltamivir (Tamiflu) was widely 25 
 5 
stockpiled and prescribed during the 2009 H1N1 pandemic despite a lack of robust evidence 1 
on its efficacy and safety for this strain, and no clinical study was conducted during the 2 
outbreak to test this.(19) The aim of the EU-FP7 project ‘PREPARE, Platform for European 3 
Preparedness against (Re-) Emerging Epidemics’ (https://www.prepare-europe.eu) is to 4 
establish a research infrastructure to transform the research response to future IDPs and 5 
includes clinical observational and interventional studies recruiting YP and children.  6 
We aimed to understand barriers and seek consensus on the priorities perceived by pediatric 7 
clinician-researchers in order to feasibly conduct pandemic-relevant pediatric clinical 8 
research in Europe. This is essential to inform pandemic study design and provide evidence 9 
for future European Commission policy and regulation.  10 
 11 
METHODS 12 
A mixed method study targeted at pediatric clinician researchers with experience of 13 
conducting pediatric ID research in Europe. Stage 1, aimed to identify challenges and 14 
priorities through a workshop and face-to face interviews. Stage 2, was an on-line survey to 15 
establish consensus on priorities.  16 
 17 
Ethical approval 18 
Cardiff University School of Medicine Research Ethics Committee approved the study.  19 
 20 
Recruitment  21 
Stage 1, Workshop and interviews: Thirty-four clinician-researchers conducting pediatric 22 
research in Europe and attending the European Society for Pediatric Infectious Diseases 23 
(ESPID) conference, Leipzig (May 2015) were identified through the PREPARE consortium 24 
(https://www.prepare-europe.eu), invited by e-mail to participate in a 2-hour workshop and to 25 
 6 
suggest additional people to invite. Those unable to attend were invited to an interview 1 
during ESPID.  2 
Stage 2, Consensus: Potential participants were identified by members of the Pediatric 3 
European Network for the Treatment of AIDS and Infectious Diseases (PENTA-ID) network 4 
(http://penta-id.org) and the PREPARE consortium. 85 pediatric clinician-researchers from 5 
17 EU and EU-associated countries were invited by personal e-mail to participate (2016). Up 6 
to three reminders were sent.  7 
 8 
Data Collection 9 
Stage 1. Workshop and interviews: A task and hypothetical scenario based topic guide was 10 
developed to guide discussions around experience and perceptions of conducting pediatric ID 11 
research and processes to facilitate IDP research. The scenarios focused on i) an adaptive 12 
pediatric ID trial of licensed pharmacological interventions in an intensive care unit (ICU) 13 
using deferred consent, and ii) an observational ID study using broad/waived consent to 14 
access clinical data and surplus/additional clinical samples. Discussions were audio-recorded 15 
and anonymised. 16 
Stage 2. Consensus survey:  Key priorities from stage 1 informed the survey. A data 17 
collection website in the English language was developed using Survey Monkey. Data were 18 
collected from 14th April to 25th August 2016. The survey comprised of 2 sections; i) 19 
demographic information (country of work, experience of research and ID outbreaks), ii) 20 
seventeen ‘research priority statements’ (with a short explanation). Participants were asked to 21 
assign a rating score (1-5, with 5 being the highest and 1 the lowest) to how important they 22 
thought each statement was to making pediatric pandemic research more feasible (national 23 
and European level). An ‘I don’t know’ option was available. Free text comments and 24 
additional priorities were invited.  25 
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 1 
Data Analysis 2 
Stage 1. Workshop and interviews: Key thematic areas were identified as patterns in 3 
participant narratives that reflected areas to facilitate IDP research. Audio-recordings were 4 
analysed by two researchers in parallel. Findings were reviewed by participants for 5 
validation. 6 
Stage 2. Consensus survey: Responses from all countries were combined.  Data were 7 
analysed in two groups: i) priority at European level and ii) national level. As an a priori cut 8 
off, ratings of 4 and 5 were considered affirmative. Statements receiving affirmative ratings 9 
from ≥70% of participants would be considered to have achieved group consensus. Median 10 
and interquartile range, and frequency distribution were calculated. Comments and additional 11 
priorities were not included in the analysis but were considered for the discussion. 12 
 13 
RESULTS 14 
Stage 1. WORKSHOP AND INTERVIEWS 15 
Participants 16 
Pediatric researcher-clinicians from 10 countries (Estonia, Finland, Greece, Germany, Italy, 17 
Lithuania, the Netherlands, Spain, Switzerland, United Kingdom) attended the workshop 18 
(n=23) or participated in an interview (n=4) at ESPID. These included 24 participants who 19 
had received an initial e-mail invitation (70.6%). All participants had conducted pediatric ID 20 
research in hospital settings. 13 had worked during an ID pandemic or outbreak.  21 
Key findings  22 
Participants discussed their experiences of conducting pediatric clinical research within and 23 
across European countries. Some significant country differences were reported, however, 24 
many common challenges were highlighted. There was general agreement that alternative 25 
 8 
approaches to conducting research are needed to conduct pediatric IDP research. Key 1 
thematic discussion areas are provided in Table 1. 2 
 3 
Table 1. Workshop and interviews: experience and perceptions of conducting pediatric 4 
ID research. 5 
Stage 2. CONSENSUS SURVEY 6 
Participants 7 
Pediatric clinician-researchers (n=39 (46% of those invited)) working in 15 countries 8 
completed the survey (Table 2). 3 had also participated in the workshop. Respondents 9 
completed all questions. 38 (95%) had experience of research in the last 5 years and 32 (80%) 10 
had experience of working in an ID outbreak including influenza like illness (n=28 (70%)), 11 
Ebola (n=4 (10%)), Dengue (n=1), SARS (n=1), Hanta virus (n=1), cholera (n=1), West Nile 12 
virus (n=1) and other ID gastrointestinal outbreaks (n=3). Other experience included 13 
laboratory research (n=17), research regulation (n=8) and social science research (n =2).  14 
 15 
Table 2. Countries in which consensus respondents conducted the majority of their 16 
work 17 
 18 
Consensus  19 
A single consensus round was conducted as all priorities exceeded the a-priori consensus 20 
criteria. Results are given in Table 3. 21 
 22 
Table 3. Priority to make pediatric epi/pandemic research more feasible at a National 23 
and European level  24 
 25 
 9 
Participants Additional Priorities 1 
Additional priorities included open access publication, ensuring rapid pan-European 2 
availability of research data, laboratory standardisation, and the establishment of research 3 
networks. 4 
 5 
 DISCUSSION 6 
IDP research that includes children and young people is essential to enable evidence-based 7 
healthcare for these populations. We identified pediatric clinician-researchers’ key priorities 8 
for facilitating this IDP research to provide evidence to research regulators and policy 9 
makers. Priority areas identified include clarity for IDP research within the European Clinical 10 
Trials Directive (Regulation), improving relationships between ethics committees and 11 
researchers, simplified regulatory processes for sharing data and clinical samples, coordinated 12 
networks for early identification of pathogens, consideration of alternative consent processes, 13 
pre-approved research protocols, improved stakeholder engagement and novel research 14 
design. These priorities are discussed below. 15 
Provision of greater clarity within the European Clinical Trial Directive for both clinical trials 16 
applying low risk procedures and observational (non-interventional) IDP pediatric studies, 17 
was a key priority for pediatric clinician researchers. (The Clinical Trials Regulation 18 
superseded the Directive following this study’s data collection). The Regulation includes a 19 
definition for observational studies; however, it includes neither a legal framework for 20 
obtaining regulatory approvals for this type of research in different EU member states nor 21 
provides guidance specifically for pediatric research in the pandemic context. This omission, 22 
in addition to a potential lack of knowledge of the new framework and pediatric ethical issues 23 
among ethics committees will pose a considerable barrier to the implementation of multi-24 
country IDP research.(20, 21). Lobbying European Commissioners for provision of greater 25 
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clarity for observational and low-risk interventional studies and including special 1 
consideration of pandemic pediatric research in the Regulation is essential to enable 2 
successful IDP studies that cannot be restricted by geographic boundaries.  3 
A breakdown in the relationship between clinician researchers and ethics committees was 4 
highlighted in the workshop and consensus. This can result in delays of approvals and some 5 
countries being excluded from pediatric ID research. Recognition of a common purpose 6 
between regulatory bodies and researchers is essential for IDP research due to the need for 7 
rapid approvals and study set up. Solutions would include education of regulators around the 8 
unique nature of ID outbreak research, setting up designated ethical committees for IDP 9 
research and preparation of pre-approved IDP ‘sleeping’ protocols, which would be ‘ready to 10 
implement’ as soon as a pandemic is officially declared. Sleeping protocols have been 11 
developed in the NIHR HTA pandemic portfolio and within the International Severe Acute 12 
Respiratory and Emerging Infection Consortium (ISARIC, https://isaric.tghn.org).(22, 23)  13 
While the collection, storage and access to clinical data and samples are essential for 14 
observational IDP research, there are currently no regulatory provisions or shared collection 15 
resources in Europe to enable this. Even within countries, access and sharing of samples and 16 
data is often disparate and difficult. If routinely collected anonymised clinical data and excess 17 
samples could be made available for research, it would reduce the need for additional studies 18 
to collect these. Coordinating IDP research with Public Health Authorities (PHAs) 19 
(responsible for surveillance, collection of samples and associated research) could be key to 20 
enabling this, with reference to countries settings where these processes have been 21 
implemented. Engagement with PHAs and other stakeholders (e.g. public health policy 22 
makers) to develop a coordinated approach and strategy may need to be driven by an 23 
International research consortium like PREPARE.  Wider consultation may need to include 24 
regulators, clinicians, patients, and members of the public to ensure understanding and 25 
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acceptability. Furthermore, embedding of research into routine clinical practice, availability 1 
of Biobanks and compliance with the 2018 General Data Protection Regulations must be 2 
considered in developing any strategy and plan to address this priority. 3 
Linked to the above is the need for establishing national and pan-European networks and 4 
shared systems to rapidly identify new pathogens and outbreak cases. Delayed information 5 
sharing can lead to delays in outbreak identification While specialist laboratories and 6 
surveillance systems exist, a European wide coordinated approach would be hard to achieve 7 
when even national implementation of shared systems was viewed as challenging in countries 8 
that have numerous healthcare systems. Alongside the set-up of shared systems, 9 
implementation of nationally agreed laboratory protocols is needed. Local laboratories may 10 
also not have the required technologies or expertise to identify new pathogens. In Australia a 11 
pediatric enhanced disease surveillance system has been established and this model may 12 
prove useful.(24)  13 
Research recruitment is a further area for discussion. It could be argued that consent 14 
requirements for IDP research may not be equivalent to those operating in non-pandemic 15 
situations and models of consent require some consideration. Deferred and opt-out consent 16 
may provide ethically valid and useful models for some observational IDP research in the 17 
emergency setting for example where collection of clinical samples for research takes place 18 
at the same time as routine sample collection or if excess sample is used.(15, 21, 25)  19 
Deferred consent is now included in the Clinical Trials Regulation, which is useful for some 20 
pandemic-relevant studies, however, there is some conflict in emergency situations.(21) Opt-21 
out consent where study information is publicised at waiting room, hospital and ward level, is 22 
implemented in some countries for observational studies, but in others regulatory and data 23 
protection agencies do not permit this. Differences in parental consent requirements for IDP 24 
research may also complicate IDP research; currently in some countries only one parent must 25 
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sign, whereas in others both parents must give written consent.(26) This may be difficult if a 1 
parent is also incapacitated or unavailable in the case of a pandemic. While variable practice 2 
in consent requirements poses a challenge in emergency research situations, cultural factors 3 
in different European countries must also be carefully considered when aiming for more 4 
universally acceptable models. Acceptance and understanding of IDP research and consent 5 
scenarios is likely to require wide public education and engagement.  6 
Stakeholder engagement, education and gaining trust are crucial for pediatric IDP research 7 
and again large ID research networks like PREPARE may be ideally placed to negotiate this. 8 
Stakeholders may include members of the public, politicians, the media and PHAs. While 9 
research to gain patient and public opinions about research has been conducted (27, 28) there 10 
is a clear need to extend this to pediatric relevant IDP research. A further need is to improve 11 
relationships and work more closely with government, as politicians were perceived as 12 
disinclined to trust scientific experts. Good media communication also becomes important as 13 
the media can influence public opinion of research potentially affecting decisions to 14 
participate in research. Closer working with public health agencies, which are among the first 15 
responders in a public health emergency such as an ID outbreak, may be critical for pandemic 16 
research.   17 
Trial design will be crucial for the pandemic or IDP or outbreak scenario. Trials with 18 
outcome-adaptive randomisation may be ideally suited to the time-sensitive pandemic setting 19 
especially if these are set-up and ready to rapidly respond in the case of an outbreak or 20 
pandemic being declared. However these designs will also need to address some ethical 21 
concerns.(29, 30) Demonstrating parent and YP acceptability of this study design and 22 
providing information to ethics committees is key to avoid delays in approvals processes.  23 
In the workshop discussions, participants briefly indicated how they had overcome some of 24 
the challenges in their ID pediatric studies. It would be useful next step to gather these 25 
 13 
scenarios in more detail to provide other researchers with knowledge of potential solutions 1 
and as evidence to facilitate regulatory approvals. 2 
STRENGTHS AND LIMITATIONS 3 
This study calls attention to a neglected area in pandemic-preparedness; pediatric clinical 4 
research. It reflects the viewpoint of pediatric clinician-researchers with experience of 5 
pediatric ID research in Europe and an understanding of IDP challenges. Most priorities were 6 
common to all participants and this commonality is a likely indication of generalisability of 7 
results to a wider group of pediatric clinician-researchers. Applicability of our initial findings 8 
to a broader group was confirmed by the survey results where the majority of respondents 9 
agreed on the priorities and proposed only a small number of additions.  10 
Sources of potential bias are the identification of participants, the required response within a 11 
limited time frame and responder bias. Only participants attending ESPID were eligible for 12 
the workshops and interviews and it could be argued that our participants were not 13 
representative of all clinician-researchers. Our participants volunteered to participate and may 14 
have had particular experiences of problematic issues in conducting pediatric research. 15 
Therefore their views may be over-represented and not generalisable to a wider group. 16 
There were some country specific differences that may be useful to explore in a subsequent 17 
study.  Describing clear examples of innovative research practice applicable to IDP research 18 
would be valuable.  19 
This study identified priority areas for change but did not develop a work plan or specific 20 
strategy for addressing each priority need. 21 
CONCLUSIONS 22 
Pediatric clinician-researchers perceived the need for key changes to facilitate pediatric IDP 23 
research. The study findings can be used to inform a strategy and action plan addressing the 24 
 14 
priority needs, to provide expert evidence to International research policy decision makers, 1 
regulators and ethics committees and to lobby for changes.  2 
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Table 1: Workshop and interviews: experience and perceptions of conducting pediatric ID 1 
research. 2 
Discussion area: Regulatory approvals across Europe 
Experience and perception:  
Increasingly difficult; increasing regulation, variability within and between countries, a lack of 
communication between regulatory bodies and discordance between ethics committees and researchers. 
Perceived solutions for IDP research might include pre-approved research protocols and a centralized 
and expedited approval system that is recognized by law in every European member state (though there 
may be problems with country acceptance). An example was provided where regional law had been 
amended (Spain) to allow observational research under a fast track approval process in a public health 
emergency (https://www.prepare-europe.eu/About-us/Workpackages/Workpackage-3)) 
Example quotes: 
 “ There is more and more legislation.. they (legislative bodies) don’t talk to each other or 
acknowledge each other.” 
 “ So much difference in the ethics permissions from committees for different centres …it is random 
and unpredictable….Some centralized approval and some de-centralized.” 
 “ Even for a retrospective chart review we could not obtain ethical approval in Spain and Italy.  We 
had to exclude them after a year of trying.” 
“ We never challenge at European level so it never gets better.” 
 “ .. even if we get endorsement at EU level…this is not accepted at country level” 
Discussion area:  Recruitment and alternative models of obtaining informed consent 
Experience and perception: 
Timely recruitment is essential for IDP research and deferred and opt-out consent for observational and 
low-risk intervention studies might be considered. Examples included opt-out consent where study 
information had been publicized at ward and hospital level (Greece, UK), and deferred consent for use 
pediatric blood samples (Spain, UK). In one Swiss centre, opt-out consent allowed clinical data and 
surplus clinical samples to be stored and accessed via an ethics application. In larger Netherlands 
hospitals, every patient needs to opt-out to prevent use of their anonymised data for observational 
research, and signatures are not needed. Acceptance of these consent models was seen as more 
problematic in some countries (Estonia, Holland, Austria, Germany). Two participants indicated that 
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obtaining prospective informed consent from parents should always be possible for IDs like influenza. 
Requirements for parental consent and child assent were also subject to country variability. Verbal 
consent was discussed and an example given where parental verbal consent was provided by telephone 
(Estonia).  
Example quotes: 
“It’s different in an epidemic (obtaining consent)….not equal to normal study consent when protecting 
a nation from epidemic disease.” 
“It has (deferred consent)… has transformed our ability to recruit children quickly….moved 
recruitment from day three to day one which is meaningful for evidence.” (UK) 
“Deferral is not right for an influenza trial, you have ten, fifteen minutes. For severe influenza there is 
time. Deferred consent is not needed and therefore not ethical.” (Netherlands)  
 “It (obtaining parental consent) is all about trust and communication.” 
Discussion area: Simplified processes for collecting and sharing clinical samples and data 
Experience and perception: 
Using and sharing clinical data and samples is important for containing outbreaks and developing 
tests. While European public health authorities conduct surveillance, their authority to initiate and 
conduct research is variable. For example, in the UK, a pediatric surveillance scheme is in place and 
the Chief Medical Officer can initiate research (including observational pandemic research and studies 
assessing the safety or effectiveness of an existing intervention with an insubstantial evidence base) 
in the interest of public health under the heading of ‘clinical service evaluation’ without ethical 
approval or consent. Some participants indicated that in countries with a federal system of 
governance a countrywide response could not be coordinated in this way (Germany, Switzerland, 
Spain). In Spain, clinical samples for public health can be obtained under a consent waiver but this is 
not the case for obtaining research samples. Collection of anonymised samples and data for 
prospective research in Spain is possible where parent/guardians consent is provided, and these 
samples can be used for research under a fast track approval process (48 hours). In the Netherlands 
anonymised surplus clinical samples can be shared for diagnostic test validation. Participants 
highlighted data protection issues, particularly during the early stages of an outbreak where it might 
be easier to link data to individuals. 
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Discussion area: Study design i.e. use of adaptive platform trial design 
Experience and perception: 
Participants were positive about adaptive design platform trials for IDP research as an alternative to 
randomised controlled trials. They felt that the design mirrors the way patients usually receive clinical 
treatment and that this might be more acceptable to parents. While the design was not thought to 
impact recruitment negatively it was viewed as potentially difficult to explain to ethics committees.  
Example quotes: 
“It (Adaptive trial design) makes a lot of sense in a pandemic. We need to learn from an epidemic as it 
goes on.” 
“It (adaptive design) might be more acceptable to parents.”  
Discussion area: Stakeholder engagement and communication 
Wider engagement to facilitate understanding of IDP research is needed. Stakeholders included 
politicians, the media, parents and young people. Public health services (PHS) were perceived as being 
more politicized than clinical services; if they identified a research need during an outbreak, then this 
would be actioned by government, whereas clinical researchers do not have any means of influencing 
government to drive the IDP research agenda. At a European level, Ministers and Chief Scientific 
Officers were perceived to be increasingly risk averse and more likely to respond rapidly to societal 
influences. Clinician-researchers should be involved in government in decisions for outbreak research 
responses. They perceived a lack of trust in the independence of scientific experts at government level. 
Establishing better relationships with the media to positively report research and help gain public trust 
was seen as important. Participants also highlighted the need for better engagement with parents and 
young people (YP) to provide education and understand their views of around participating in IDP 
research, use of clinical samples and data, and consent models. This can be time consuming but should 
be possible for pre-approved protocols and would aid acceptability by ethics committees.  
Example quote: 
“ Increasingly ministers are more risk averse. Politicians are younger and not used to dealing with a 
crisis…less prepared to wait and see..much more aware of societal influences. They don’t believe in 
independence of scientific experts…viewing scientific advice with suspicion… puts us in a fragile 
position.” (UK) 
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Discussion area: Recognizing the importance of pediatric pandemic research 
Participants briefly discussed the evidence gap for pediatric clinical practice around IDs and the 
practice of using off-label antibiotic prescribing in these populations with parents generally being 
unaware of this.  
 1 
 2 
Table 2. Countries in which consensus respondents conducted the majority of their work 3 
Country Number Country Number Country Number 
UK 7 Estonia 2 Romania 1 
Spain 7 Austria 1 Slovenia 1 
Germany 5 Finland 1 aMontenegro 1 
Greece 3 France 1 bSwitzerland 1 
Belgium 2 Italy 1 Unknown 1 
The 
Netherlands 
2 Portugal 1 cMultiple 
countries 
1 
aMontenegro is included, as this country has started the process of accession to the EU. bSwitzerland is included as an EU 4 
associated country and as research networks in Switzerland are included in PREPARE. cParticipant stated that they worked 5 
in ‘multiple countries’ and did not provide a specific country of work. 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
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Table 3. Priority to make pediatric epi/pandemic research more feasible at a National and European level 1 
(median and interquartile range (IQR) for each rated statement 2 
Area N
o. 
Area required to make pediatric epi/pandemic research 
more feasible at a National and European level 
Priority at 
National 
Level 
Rated scores 
Median 
(IQR)  
(1-low 
priority) to 
5-high 
priority) 
Priority at 
European 
Level 
Rated 
scores 
Median 
(IQR) 
(1-low 
priority) to  
5-high 
priority)  
EU Directive 1 Clarity within the new clinical trials Directive for 
epi/pandemic observational research including children  
a5.00 
 (5.00-4.00) 
2 Clarity within the new clinical trials Directive for 
epi/pandemic clinical trials including children 
a5.00 
(5.00-4.00) 
Regulatory 
processes 
3 Recognition of a common purpose and improved relationship 
between regulatory bodies, ethics committees and 
researchers  
5.00 
(5.00-4.00) 
5.00 
(5.00-4.00) 
4 Simplified regulatory processes for observational research 
involving collection, use and sharing of anonymised clinical 
data (relevant to infectious disease epi/pandemics).    
5.00 
(5.00-4.00) 
5.00 
(5.00-4.00) 
5 Simplified regulatory processes for research involving the 
collecting, using and sharing of anonymised surplus clinical 
samples (relevant to infectious disease epi/pandemics).  
5.00 
(5.00-4.00) 
5.00 
(5.00-3.25) 
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Pre-approved 
protocols 
6 Acceptance of pre-approved protocols for epi/pandemic 
research 
4.00 
(5.00-4.00) 
4.00 
(5.00-4.00) 
Alternative 
consent 
models 
7 Regulatory approval of alternative models of obtaining 
patient informed consent for research involving the use of 
clinical data in an epi/pandemic  
4.00 
(5.00-4.00) 
4.00 
(5.00-3.25) 
8 Coordinated processes for the early identification of potential 
new outbreak cases and pathogens 
4.00 
(5.00-4.00) 
4.00 
(5.00-3.00) 
9 Regulatory approval of alternative models of obtaining 
patient informed consent for research involving the use of 
clinical samples (excluding genetic testing) in an 
epi/pandemic (e.g. deferred consent, opt-out consent, and 
alternatives to written consent).  
4.00 
(5.00-4.00) 
 
4.00 
(5.00-3.00) 
 
10 Regulatory approval of alternative models of obtaining 
patient informed consent for ‘low risk’ research trials (e.g. 
comparative effectiveness) in an epi/pandemic (e.g. deferred 
consent, opt-out consent, and alternatives to written 
consent). 
4.00 
(4.75-4.00) 
4.00 
(5.00-3.00) 
11 Regulatory approval of alternative models of obtaining 
patient informed consent for ‘high risk’ research trials (e.g. 
novel agent) in an epi/pandemic (e.g. deferred consent, opt-
out consent, and alternatives to written consent). 
4.00 
(5.00-3.00) 
4.00 
(5.00-3.00) 
Adaptive trial 
design 
13 Recognition of the benefits of novel trial designs e.g. adaptive 
platform trials by regulatory and ethics committees 
4.00 
(5.00-3.25) 
4.00 
(5-3.25) 
Communication 
and trust 
14 Good two-way communicating between researchers and 
senior government regarding research requirements for 
emerging infectious disease outbreaks 
4.00 
(5.00-4.00) 
4.00 
(5.00-4.00) 
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a Not asked to discriminate between National and European level 1 
 2 
 3 
 4 
 5 
 6 
 7 
12 Establishing trust between researchers and senior 
government regarding research requirements for emerging 
infectious disease outbreaks 
4.00 
(5.00-4.00) 
4.00 
(5.00-4.00) 
15 A strategy for engagement and good communications with 
the media to aid positive reporting of research for IDPs 
including children 
a4.00 
(5.00-4.00) 
16 Parent and young person engagement and education about 
epi/pandemic research 
a4.00 
(5.00-3.00) 
Training 17 Training of front-line clinical staff in the procedures of pre-
approved protocols for epi/pandemic research 
4.00 
(5.00-3.00) 
 
4.00 
(5.00-3.00) 
(at local 
level) 
